Status:
RECRUITING
Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients
Lead Sponsor:
Baylor College of Medicine
Collaborating Sponsors:
Southern Star Research
Conditions:
Vascular Ehlers-Danlos Syndrome
Eligibility:
All Genders
12-45 years
Phase:
NA
Brief Summary
Vascular Ehlers-Danlos Syndrome (VEDS) is caused by pathogenic variants of the COL3A1 gene, resulting abnormal Type III collagen protein. This impacts the body's connective tissue and makes people wit...
Detailed Description
Vascular Ehlers Danlos Syndrome (VEDS) is caused by pathogenic variants of the COL3A1 gene, resulting abnormal Type III collagen protein. This impacts the body's connective tissue and makes people wit...
Eligibility Criteria
Inclusion
- Participants must be diagnosed with Vascular Ehlers-Danlos Syndrome verified by a mutation of the COL3A1 gene
- Ages 12-45 year at the time of enrollment
- Access to a smartphone as well as an additional device with camera and microphone
- Stable internet access
- English speaking
Exclusion
- Non-English speakers
- Any conditions or developmental delays limiting the ability to utilize technology or follow directions.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2028
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05994664
Start Date
April 1 2024
End Date
January 1 2028
Last Update
July 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Texas Children's Hospital
Houston, Texas, United States, 77030